Перейти к главному меню навигации Перейти к основному контенту Перейти к нижнему колонтитулу сайта

№ 2 (2023)

НОВЫЕ ЛЕКАРСТВЕННЫЕ СРЕДСТВА

Антипсихотик третьего поколения карипразин как перспективный препарат для терапии депрессивных расстройств

https://doi.org/10.21265/PSYPH.2023.86.41.003

Опубликован 2023-06-30

  • Р. Ф. Насырова

Р. Ф. Насырова
Национальный медицинский исследовательский центр психиатрии и неврологии имени В.М. Бехтерева

Аннотация

Карипразин в настоящее время одобрен для лечения пациентов с депрессивными и смешанными эпизодами биполярного расстройства I типа, кроме того в нескольких рандомизированных контролируемых исследованиях также изучалась его эффективность у пациентов с рекуррентным депрессивным расстройством. В обзоре обобщены потенциальные преимущества карипразина для лечения основных симптомов биполярного расстройства I типа и большого депрессивного расстройства с учетом его фармакодинамических свойств, эффективности и переносимости. Его преимущественное сродство к рецептору D3 с функциональной избирательностью в соответствии с преобладающим нейронным окружением способствует его эффективности при широком спектре психопатологических симптомов (включая расстройство настроения, ангедонию и когнитивные нарушения), высокой безопасности и хорошей переносимости.

Ключевые слова

карипразин, рекуррентное депрессивное расстройство, биполярное расстройство, антипсихотики третьего поколения, механизм действия

PDF

Библиографические ссылки

  1. Villanueva R. Neurobiology of major depressive disorder // Neural Plasticity. – 2013. – Vol. 2013. – Art. 873278. – https://doi.org/10.1155/2013/873278
  2. Mergl R. et al. Depressive, anxiety, and somatoform disorders in primary care: prevalence and recognition / /Depression and Anxiety. – 2007. – Vol. 24, no. 3. – Pp. 185–195. – https://doi.org/10.1002/da.20192
  3. Sheehan D.V. Establishing the real cost of depression // Managed Care (Langhorne, Pa.). – 2002. – Vol. 11, no. 8, suppl. – Pp. 7–25.
  4. Dean J., Keshavan M. The neurobiology of depression: An integrated view // Asian Journal of Psychiatry. – 2017. – Vol. 27. – Pp. 101–111. – https://doi.org/10.1016/j.ajp.2017.01.025
  5. Мосолов С.Н. Современные биологические гипотезы рекуррентной депрессии (обзор) // Журнал неврологии и психиатрии имени В.В. Корсакова. – 2012. – Т. 112, № 11-2. – С. 29–40.
  6. Алфимов Р.В., Костюкова Е.Г., Мосолов С.Н. Методы преодоления терапевтической резистентности при рекуррентных депрессиях // Биологические методы терапии психических расстройств. Доказательная медицина – клинической практике. – М.: Социальнополитическая мысль, 2012. – С. 438–473.
  7. Perez-Caballero L. et al. Monoaminergic system and depression // Cell and Tissue research. – 2019. – Vol. 377. – Pp. 107–113. – https://doi.org/10.1007/s00441-018-2978-8
  8. Lang U.E., Borgwardt S. Molecular mechanisms of depression: perspectives on new treatment strategies // Cellular Physiology and Biochemistry. – 2013. – Vol. 31, no. 6. – Pp. 761–777. – https://doi.org/10.1159/000350094
  9. Blier P., Blondeau C. Neurobiological bases and clinical aspects of the use of aripiprazole in treatment-resistant major depressive disorder // Journal of Affective Disorders. – 2011. – Vol. 128. – Pp. S3–S10. – https://doi.org/10.1016/S0165-0327(11)70003-9
  10. Horacek J. et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia // CNS Drugs. – 2006. – Vol. 20. – Pp. 389–409. – https://doi.org/10.2165/00023210-200620050-00004
  11. Carlsson A. Dopamine receptor agonists: intrinsic activity vs. state of receptor // Journal of Neural Transmission. – 1983. – Vol. 57. – Pp. 309–315. – https://doi.org/10.1007/BF01249001
  12. Keltner N.L., Johnson V. Aripiprazole: a third generation of antipsychotics begins? // Perspectives in Psychiatric Care. – 2002. – Vol. 38, no. 4. – Art. 157. – https://doi.org/10.1111/j.1744-6163.2002.tb01566.x
  13. Mailman R.B., Murthy V. Third generation antipsychotic drugs: partial agonism or receptor functional selectivity? // Current Pharmaceutical Design. – 2010. – Vol. 16, no. 5. – Pp. 488–501. – https://doi.org/10.2174/138161210790361461
  14. Rybakowski J. Etiopathogenesis of bipolar affective disorder-the state of the art for 2021 // Psychiatria Polska. – 2021. – Vol. 55, no. 3. – Pp. 481–496. – https://doi.org/10.12740/pp/132961
  15. Ceskova E., Silhan P. Novel treatment options in depression and psychosis // Neuropsychiatric Disease and Treatment. – 2018. – Vol. 14. – Pp. 741–747. – https://doi.org/10.2147/NDT.S157475
  16. Hamon M., Blier P. Monoamine neurocircuitry in depression and strategies for new treatments // Progress in Neuro-Psychopharmacology and Biological Psychiatry. – 2013. – Vol. 45. – Pp. 54–63. – https://doi.org/10.1016/j.pnpbp.2013.04.009
  17. Carlsson A. The contribution of drug research to investigating the nature of endogenous depression // Pharmacopsychiatry. – 1976. – Vol. 9
  18. De Deurwaerdère P., Di Giovanni G. Serotonergic modulation of the activity of mesencephalic dopaminergic systems: therapeutic implications // Progress in Neurobiology. – 2017. – Vol. 151. – Pр. 175–236. – https://doi.org/10.1016/j.pneurobio.2016.03.004
  19. Grinchii D., Dremencov E. Mechanism of action of atypical antipsychotic drugs in mood disorders // International Journal of Molecular Sciences. – 2020. – Vol. 21, no. 24. – Art. 9532. – https://doi.org/10.3390/ijms21249532
  20. Ślifirski G., Król M., Turło J. 5-HT receptors and the development of new antidepressants // International Journal of Molecular Sciences. – 2021. – Vol. 22, no. 16. – Art. 9015. – https://doi.org/10.3390/ijms22169015
  21. Eshel N. et al. Dopamine neurons share common response function for reward prediction error // Nature Neuroscience. – 2016. – Vol. 19, no. 3. – Pp. 479–486.– https://doi.org/10.1038/nn.4239
  22. Wise R.A. Dopamine, learning and motivation // Nature Reviews Neuroscience. – 2004. – Vol. 5, no. 6. – Pp. 483–494. – https://doi.org/10.1038/nrn1406
  23. Wise R.A. Dopamine and reward: the anhedonia hypothesis 30 years on // Neurotoxicity Research. – 2008. – Vol. 14. – Pр. 169-183.– https://doi.org/10.1007/BF03033808
  24. Pandit R. et al. Melanocortin 3 receptor signaling in midbrain dopamine neurons increases the motivation for food reward // Neuropsychopharmacology. – 2016. – Vol. 41, no. 9. – Pp. 2241–2251.– https://doi.org/10.1038/npp.2016.19
  25. Grace A.A. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression // Nature Reviews Neuroscience. – 2016. – Vol. 17, no. 8. – Pp. 24– 532. – https://doi.org/10.1038/nrn.2016.57.
  26. Sultan K.T., Brown K.N., Shi S.H. Production and organization of neocortical interneurons // Frontiers in Cellular Neuroscience. – 2013. – Vol. 7. – Art. 221. – https://doi.org/10.3389/fncel.2013.00221
  27. Buzsaki G., Draguhn A. Neuronal oscillations in cortical networks // Science. – 2004. – Vol. 304, no. 5679. – Pp. 1926–1929.– https://doi.org/10.1126/science.1099745
  28. Steullet P. et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a “central hub” in schizophrenia pathophysiology? // Schizophrenia Research. – 2016. – Vol. 176, no. 1. – Pp. 41–51. – https://doi.org/10.1016/j.schres.2014.06.021
  29. Taliaz D. et al. Knockdown of brain-derived neurotrophic factor in specific brain sites precipitates behaviors associated with depression and reduces neurogenesis // Molecular Psychiatry. – 2010. – Vol. 15, no. 1. – Pp. 80–92. – https://doi.org/10.1038/mp.2009.67
  30. Krishnan V., Nestler E.J. The molecular neurobiology of depression // Nature. – 2008. – Vol. 455, no. 7215. – Pp. 894–902. – https://doi.org/10.1038/nature07455
  31. Hall J., Thomas K.L., Everitt B.J. Rapid and selective induction of BDNF expression in the hippocampus during contextual learning // Nature Neuroscience. – 2000. – Vol. 3, no. 6. – Pp. 533–535. – https://doi.org/10.1038/75698
  32. Li P., Snyder G.L., Vanover S.E., Vanover K.E. Dopamine targeting drugs for the treatment of schizophrenia: Past, present and future // Current Topics in Medicinal Chemistry. – 2016. – Vol. 16, no. 29. – Pp. 3385–3403. – https://doi.org/10.2174/1568026616666160608084834
  33. Martinowich K., Lu B. Interaction between BDNF and serotonin: role in mood disorders // Neuropsychopharmacology. – 2008. – Vol. 33, no. 1. – Pp. 73–83. – https://doi.org/10.1038/sj.npp.1301571
  34. Szapacs M.E. et al. Exploring the relationship between serotonin and brain-derived neurotrophic factor: analysis of BDNF protein and extraneuronal 5-HT in mice with reduced serotonin transporter or BDNF expression // Journal of Neuroscience Methods. – 2004. – Vol. 140, no. 1–2. – Pp. 81–92. – https://doi.org/10.1016/j.jneumeth.2004.03.026
  35. Santarelli L. et al. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants // Science. – 2003. – Vol. 301, no. 5634. – Pp. 805–809. – https://doi.org/10.1126/science.1083328
  36. Surget A. et al. Antidepressants recruit new neurons to improve stress response regulation // Molecular Psychiatry. – 2011. – Vol. 16, no. 12. – Pp. 1177–1188. – https://doi.org/10.1038/mp.2011.48
  37. Mateus-Pinheiro A. et al. Sustained remission from depressive-like behavior depends on hippocampal neurogenesis // Translational Psychiatry. – 2013. – Vol. 3, no. 1. – Pp. e210-e210. – https://doi.org/10.1038/tp.2012.141
  38. Chikama K. et al. Chronic atypical antipsychotics, but not haloperidol, increase neurogenesis in the hippocampus of adult mouse // Brain Res. – 2017. – Vol. 1676. – Pp. 77–82. – https://doi.org/10.1016/j.brainres.2017.09.006
  39. Patrício P. et al. Differential and converging molecular mechanisms of antidepressants’ action in the hippocampal dentate gyrus // Neuropsychopharmacology. – 2015. – Vol. 40, no. 2. – Pp. 338–349. – https://doi.org/10.1038/npp.2014.176
  40. Bessa J.M. et al. The mood-improving actions of antidepressants do not depend on neurogenesis but are associated with neuronal remodeling // Molecular Psychiatry. – 2009. – Vol. 14, no. 8. – Pp. 764–773. – https://doi.org/10.1038/mp.2008.119
  41. Mateus-Pinheiro A. et al. Sustained remission from depressive-like behavior depends on hippocampal neurogenesis // Translational Psychiatry. – 2013. – Vol. 3, no. 1. – Pp. e210–e210. – https://doi.org/10.1038/tp.2012.141
  42. Wang H.D., Deutch A.Y. Dopamine depletion of the prefrontal cortex induces dendritic spine loss: reversal by atypical antipsychotic drug treatment // Neuropsychopharmacology. – 2008. – Vol. 33, no. 6. – Pp. 1276–1286. – https://doi.org/10.1038/sj.npp.1301521
  43. Morais M. et al. The modulation of adult neuroplasticity is involved in the mood-improving actions of atypical antipsychotics in an animal model of depression // Translational psychiatry. – 2017. – Vol. 7, no. 6. – Pp. e1146–e1146. – https://doi.org/10.1038/tp.2017.120
  44. Schildkraut J.J. The catecholamine hypothesis of affective disorders: a review of supporting evidence // American Journal of Psychiatry. – 1965. – Vol. 122, no. 5. – Pp. 509–522. – https://doi.org/10.1176/ajp.122.5.509
  45. Bunney W.E. The current status of research in the catecholamine theories of affective disorders // Psychopharmacology Communications. – 1975. – Vol. 1, no. 6. – Pp. 599–609.
  46. Ashok A. et al. The dopamine hypothesis of bipolar affective disorder: the state of the art and implications for treatment // Molecular Psychiatry. – 2017. – Vol. 22. – Pp. 666–679. – https://doi.org/10.1038/mp.2017.16
  47. Yatham L.N. et al. A positron emission tomography study of dopamine transporter density in patients with bipolar disorder with current mania and those with recently remitted mania // JAMA Psychiatry. – 2022. – Vol. 79, no. 12. – Pp. 1217–1224. – https://doi.org/10.1001/jamapsychiatry.2022.3541
  48. Jensen N.H. et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, a putative mediator of quetiapine’s antidepressant activity // Neuropsychopharmacology. – 2008. – Vol. 33. – Pp. 2303–2312. – https://doi.org/10.1038/sj.npp.1301646
  49. Tuppurainen H. et al. Extrapyramidal side-effects and dopamine D(2/3) receptor binding in substantia nigra // Nord J Psychiatry. – 2010 – Vol. 64, no. 4. – Pp. 233–238. – https://doi.org/10.3109/08039480903484076
  50. Durgam S. et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression // American Journal of Psychiatry. – 2016. – Vol. 173, no. 3. – Pp. 271–281. – https://doi.org/10.1176/appi.ajp.2015.15020164
  51. Медведев В.Э. Карипразин — современный препарат для лечения шизофрении и биполярного расстройства // Современная терапия психических расстройств. – 2022. – № 3. – С. 51–57. – https://doi.org/10.21265/PSYPH.2022.46.63.006
  52. Durgam S. et al. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder // The Journal of Clinical Psychiatry. – 2016. – Vol. 77, no. 3. – Art. 6112. – https://doi.org/10.4088/JCP.15m10070
  53. Kiss B., Horti F., Bobok A. Poster# 16 cariprazine, a D3/D2 dopamine receptor partial agonist antipsychotic, displays greater D3 receptor occupancy in vivo compared with other antipsychotics // Schizophrenia Research. – 2012. – No. 136. – Art. S190.– https://doi.org/10.1016/S0920-9964(12)70588-1
  54. Slifstein M. et al. Cariprazine demonstrates high dopamine D3 and D2 receptor occupancy in patients with schizophrenia: a clinical PET study with [11C]-(+)-PHNO // Neuropsychopharmacology. – 2013. – Vol. 38. – Pp. S520–S521.
  55. Tohen M. Cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults: an evidence-based review of recent data // Drug Design, Development and Therapy. – 2021. – Vol. 15. – Pp. 2005–2012. – https://doi.org/10.2147/DDDT.S240860
  56. Петрова Н.Н. Расстройства аутистического спектра во взрослом возрасте. Обзор // Психиатрия, Психотерапия и Клиническая Психология. – 2022. – Т.13, № 2. – С. 179- 191. – https://doi.org/10.34883/PI.2022.13.2.003
  57. Yatham L.N. et al. A positron emission tomography study of dopamine transporter density in patients with bipolar disorder with current mania and those with recently remitted mania // JAMA Psychiatry. – 2022. – Vol. 79, no. 12. – Pp. 1217–1224. – https://doi.org/10.1001/jamapsychiatry.2022.3541
  58. Ragguett R.M., McIntyre R.S. Cariprazine for the treatment of bipolar depression: a review // Expert Rev Neurother. – 2019. – Vol. 19, no. 4. – Pp. 317–323. – httpd://doi.org/10.1080/14737175.2019.1580571
  59. McIntyre R.S., Suppes T., Earley W., Patel M., Stahl S.M. Cariprazine efficacy in bipolar I depression with and without concurrent manic symptoms: post hoc analysis of 3 randomized, placebo-controlled studies // CNS spectrums. – 2020. – Vol. 25, no. 4. – Pp. 502– 510. – https://doi.org/10.1017/S1092852919001287
  60. Lam R.W. et al. Combining antidepressants for treatment-resistant depression: a review // Journal of Clinical Psychiatry. – 2002. – Vol. 63, no. 8. – Pp. 685–693. – https://doi.org/10.4088/jcp.v63n0805
  61. Nelson J.C., Papakostas G.I. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials // American Journal of Psychiatry. – 2009. – Vol. 166, no. 9. – Pp. 980–991. – https://doi.org/10.1176/appi.ajp.2009.09030312
  62. Wright B.M., Eiland III E.H., Lorenz R. Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature // Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. – 2013. – Vol. 33, no. 3. – Pp. 344–359. – https://doi.org/10.1002/phar.1204
  63. Earley W.R. et al. Cariprazine augmentation to antidepressant therapy in major depressive disorder: results of a randomized, double-blind, placebo-controlled trial // Psychopharmacology Bulletin. – 2018. – Vol. 48, no. 4. – Pp. 62–80.
  64. Pinto J.V. et al. Cariprazine in the treatment of Bipolar Disorder: A systematic review and meta-analysis // Bipolar Disorders. – 2020. – Vol. 22, no. 4. – Pp. 360–371. – https://doi.org/10.1111/bdi.12850
  65. Vieta E. et al. Long-term safety and tolerability of cariprazine as adjunctive therapy in major depressive disorder // International Clinical Psychopharmacology. – 2019. – Vol. 34, no. 2. – Pp. 76–83. – https://doi.org/10.1097/YIC.0000000000000246
  66. Fava M. et al. Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial // International Clinical Psychopharmacology. – 2018. – Vol. 33, no. 6. – Pp. 312–321. – https://doi.org/10.1097/YIC.0000000000000235
  67. Bahji A. et al. Comparative efficacy and tolerability of pharmacological treatments for the treatment of acute bipolar depression: a systematic review and network meta-analysis // Journal of Affective Disorders. – 2020. – Vol. 269. – Pp. 154–184. – https://doi.org/10.1016/j.jad.2020.03.030
  68. Batinic B. et al. Assessment of cognitive function, social disability and basic life skills in euthymic patients with bipolar disorder // Psychiatr Danub. – 2021. – Vol. 33, no. 3. – Pp. 320–327. – https://doi.org/10.24869/psyd.2021.320
  69. Tabarés-Seisdedos R. et al. Neurocognitive and clinical predictors of functional outcome in patients with schizophrenia and bipolar I disorder at one-year follow-up // J Affect Disord. – 2008 – Vol. 109, no. 3. – Pp. 286–299. – https://doi.org/10.1016/j.jad.2007.12.234
  70. Huang M. et al. The role of dopamine D3 receptor partial agonism in cariprazine-Induced neurotransmitter efflux in rat hippocampus and nucleus accumbens // J Pharmacol Exp Ther. – 2019 – Vol. 371, no. 2. – Pp. 517–525. – https://doi.org/10.1124/jpet.119.259879
  71. Zimnisky R. et al. Cariprazine, a dopamine D(3)-receptor-preferring partial agonist, blocks phencyclidine-induced impairments of working memory, attention set-shifting, and recognition memory in the mouse // Psychopharmacology (Berl). – 2013. – Vol. 22. – Pp. 91– 100. – https://doi.org/10.1007/s00213-012-2896-5
  72. Stahl S. Drugs for psychosis and mood: unique actions at D3, D2, and D1 dopamine receptor subtypes // CNS Spectr. – 2017. – Vol. 22, no. 5. – Pp. 375–384. – https://doi.org/10.1017/S1092852917000608
  73. Calabrese F. et al. The role of dopamine D3 receptors in the mechanism of action of cariprazine // CNS Spectrums. – 2020. – Vol. 25, no. 3. – Pp. 343–351. – https://doi.org/10.1017/S109285291900083X 7
  74. Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy // Adv Ther. – 2013. – Vol. 30, no. 2. – Pp. 114–126. – https://doi.org/10.1007/s12325-013-0006-7
  75. Citrome L. Cariprazine for bipolar depression: What is the number needed to treat, number needed to harm and likelihood to be helped or harmed? // Int J Clin Pract. – 2019. – Vol. 73, no. 10. – Art. 13397. – https://doi.org/10.1111/ijcp.13397
  76. Nakamura T. et al. Clinical pharmacology study of cariprazine (MP-214) in patients with schizophrenia (12-week treatment) // Drug Des Devel Ther. – 2016. – Vol. 10. – Pp. 327–338. – https://doi.org/10.2147/DDDT.S95100
  77. Caccia S. et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia // Therapeutics and Clinical Risk Management. – 2013. – Vol. 9. – Pp. 319–328. – https://doi.org/10.2147/TCRM.S35137
  78. Мосолов С.Н., Алфимов П.В. Роль дофаминовых D3-рецепторов в механизме действия современных антипсихотиков // Современная терапия психических расстройств. – 2014. – № 1. – С. 2-9.
  79. Earley W. et al. Efficacy of cariprazine on negative symptoms in patients with acute schizophrenia: a post hoc analysis of pooled data // Schizophrenia Research. – 2019. – Vol. 204. – Pp. 282–288. – https://doi.org/10.1016/j.schres.2018.08.020
  80. Mohr P., Masopust J., Kopeček M. Dopamine receptor partial agonists: Do they differ in their clinical efficacy? // Frontiers in Psychiatry. – 2022. – Vol. 12. – Art. 2491. – https://doi.org/10.3389/fpsyt.2021.781946
  81. Forte A. et al. Long-term morbidity in bipolar-I, bipolar-II, and unipolar major depressive disorders // J Affect Disord. – 2015 – Vol. 178. – Pp. 71–78. – https://doi.org/10.1016/j.jad.2015.02.011
  82. Rancans E. et al.The effectiveness and safety of cariprazine in schizophrenia patients with negative symptoms and insufficient effectiveness of previous antipsychotic therapy: an observational study // Int Clin Psychopharmacol. – 2021 – Vol. 36, no. 3. – Pp. 154–161. – https://doi.org/10.1097/YIC.0000000000000351

Скачивания

Данные скачивания пока недоступны.